Restricted accessResearch articleFirst published online 2019-10
Efficient Screening and Design of Variable Domain of Heavy Chain Antibody Ligands Through High Throughput Sequencing for Affinity Chromatography to Purify Fab Fragments
To design an affinity ligand for purification of antigen-binding fragment (Fab) antibody, variable domain of heavy chain antibody (VHH) phage libraries were constructed from Fab-immunized Alpaca and subjected to biopanning against Fabs. To find the specific binders, we directly applied high-throughput sequencing (HTS) analysis of the VHH sequences in the panned phages on next-generation sequencer. The efficiently enriched sequences were aligned for construction of the phylogenetic tree to be categorized into five groups. VHHs from three major groups were first selected to analyze their properties as an affinity ligand. However, those VHHs were not suitable as an affinity ligand because of lack of resistance against alkaline pH and/or difficulty in acidic elution from the affinity column. So, we further searched the candidates from minor group sequences. Among five, one VHH showed the binding ability but with low affinity against Fabs. Therefore, we improved its affinity-by-affinity maturation through error-prone PCR library techniques. The final designed VHH showed highly alkaline pH resistance and easy acidic elution together with high affinity to Fabs. These results indicate that HTS techniques combined with biopanning and followed by error-prone PCR library techniques is powerful in designing specific binders with desired properties.
Get full access to this article
View all access options for this article.
References
1.
EckerDM, JonesSD, and LevineHL: The therapeutic monoclonal antibody market. mAbs, 2015; 7:9–14.
2.
ChamesP, Van RegenmortelM, WeissE, and BatyD: Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol, 2009; 157:220–233.
3.
ChoiDK, BaeJ, ShinSM, ShinJY, KimS, and KimYS: A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells. mAbs, 2014; 6:1402–1414.
4.
HolligerP, and HudsonPJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol, 2005; 23:1126–1136.
5.
FittingJ, BlumeT, TenHA, BlauW, GattenlöhnerS, TurMK, and BarthS: Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. mAbs, 2015; 7:390–402.
6.
KholodenkoRV, KalinovskyDV, DoroninII, PonomarevED, and KholodenkoIV: Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. Curr Med Chem, 2019; 26:396–426.
7.
SchefferGL, ReursAW, JuttenB, BeiboerSHW, Van AmerongenR, SchoesterM, WiemerEAC, HoogenboomHR, and ScheperRJ: Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein. Br J Cancer, 2002; 86:954–962.
8.
ParrenPWHI, and LugovskoyAA: Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry. mAbs, 2013; 5:175–177.
9.
NelsonAL: Antibody fragments: Hope and hype. mAbs, 2010; 2:77–83.
NelsonAL, and ReichertJM: Development trends for therapeutic antibody fragments. Nat Biotechnol, 2009; 27:331–337.
12.
BjörckL: Protein L: A novel bacterial cell wall protein with affinity for Ig L chains. J Immunol, 1988; 140:1194–1197.
13.
WillemsA, LeoenJ, SchoonoogheS, GrootenJ, and MertensN: Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J Chromatogr BAnalyt Technol Biomed Life Sci, 2003; 786:161–176.
14.
De ChateauM, NilsonBH, ErntellM, MyhreE, MagnussonCG, AkerstromB, and BjorckL: On the Interaction between Protein L and immunoglobulins of various mammalian species. Scand J Immunol, 1993; 37:399–405.
15.
ScanlanC: Downstream Purification and formulation of Fab antibody fragments. BioPharm Int, 2014; 27:502–520.
16.
EiflerN, MedagliaG, AnderkaO, LaurinL, and HermansP: Development of a novel affinity chromatography resin for platform purification of lambda fabs. Biotechnol Prog, 2014; 30:1311–1318.
17.
RodrigoG, and GrönlundS: Platform approaches for the purification of antibody fragments. BioProcess Int, 2012 [Epub ahead of print]; DOI:10.1016/j.addbeh.2008.11.009.
18.
HageDS: Affinity chromatography: A review of clinical applications. Clin Chem, 1999; 45:593–615.
19.
UrhM, SimpsonD, and ZhaoK: Affinity Chromatography. General Methods. Methods Enzymol, 2009; 463:417–438.
20.
Hamers-CastermanC, AtarhouchT, MuyldermansS, RobinsonG, HammersC, BajyanaEB, BendahmanN, and HammersR: Naturally occurring antibodies devoid of light chains. Nature, 1993; 363:446–448.
21.
MuyldermansS: Nanobodies: Natural Single-Domain Antibodies. Annu Rev Biochem, 2013; 82:775–797.
22.
HarmsenMM, and De HaardHJ: Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol, 2007; 77:13–22.
23.
DumoulinM, ConrathK, Van MeirhaegheA, MeersmanF, HeremansK, FrenkenLG, MuyldermansS, WynsL, and MatagneA: Single-domain antibody fragments with high conformational stability. Protein Sci, 2002; 11:500–515.
24.
Arbabi GhahroudiM, DesmyterA, WynsL, HamersR, and MuyldermansS: Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett, 1997; 414:521–526.
25.
PérezJMJ, RenisioJG, PrompersJJ, Van PlaterinkCJ, CambillauC, DarbonH, and FrenkenLGJ: Thermal unfolding of a llama antibody fragment: A two-state reversible process. Biochemistry, 2001; 40:74–83.
26.
LadensonRC, CrimminsDL, LandtY, and LadensonJH: Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal Chem, 2006; 78:4501–4508.
27.
OmidfarK, RasaeeMJ, KashanianS, PaknejadM, and BathaieZ: Studies of thermostability in Camelus bactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia. Biotechnol Appl Biochem, 2007; 46:41–49.
28.
EwertS, CambillauC, ConrathK, and PlückthunA: Biophysical properties of camelid V HH domains compared to those of human V H 3 domains. Biochemistry, 2002; 41:3628–3636.
29.
Arbabi-GhahroudiM, TanhaJ, and MacKenzieR: Prokaryotic expression of antibodies. Cancer Metastasis Rev, 2005; 24:501–519.
30.
TanhaJ, NguyenTD, NgA, RyanS, NiF, and MacKenzieR: Improving solubility and refolding efficiency of human VHs by a novel mutational approach. Protein Eng Des Sel, 2006; 19:503–509.
31.
FrenkenLGJ, Van Der LindenRHJ, HermansPWJJ, BosJW, RuulsRC, De GeusB, and VerripsCT: Isolation of antigen specific Llama V(HH) antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol, 2000; 78:11–21.
32.
GriffithsAD, WilliamsSC, HartleyO, TomlinsonIM, WaterhouseP, CrosbyWL, KontermannRE, JonesPT, LowNM, and AllisonTJ: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J, 1994; 13:3245–3260.
33.
MuraokaS, ItoY, KamimuraM, BabaM, ArimaN, SudaY, HashiguchiS, TorikaiM, NakashimaT, and SugimuraK: Effective induction of cell death on adult T-cell leukaemia cells by HLA-DRβ-specific small antibody fragment isolated from human antibody phage library. J Biochem, 2009; 145:799–810.
34.
DekoskyBJ, IppolitoGC, DeschnerRP, LavinderJJ, WineY, RawlingsBM, VaradarajanN, GieseckeC, DörnerT, AndrewsSF, WilsonPC, Hunicke-SmithSP, WillsonCG, EllingtonAD, and GeorgiouG: High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol, 2013; 31:166–169.
35.
ReddyST, GeX, MiklosAE, HughesRA, KangSH, HoiKH, ChrysostomouC, Hunicke-SmithSP, IversonBL, TuckerPW, EllingtonAD, and GeorgiouG: Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol, 2010; 28:965–969.
36.
ZhuJ, OfekG, YangY, ZhangB, LouderMK, LuG, McKeeK, PanceraM, SkinnerJ, ZhangZ, ParksR, EudaileyJ, LloydKE, BlinnJ, AlamSM, HaynesBF, SimekM, BurtonDR, KoffWC, MullikinJC, MascolaJR, ShapiroL, and KwongPD: Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci USA, 2013; 110:6470–6475.
37.
ClarkLA, Boriack-SjodinPA, EldredgeJ, FitchC, FriedmanB, HanfKJM, JarpeM, LiparotoSF, LiY, LugovskoyA, MillerS, RusheM, ShermanW, SimonK, and Van VlijmenH: Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci, 2006; 15:949–960.
38.
AntikainenNM, and MartinSF: Altering protein specificity: Techniques and applications. Bioorg Med Chem, 2005; 13:2701–2716.
39.
BilesBD, and ConnollyBA: Low-fidelity Pyrococcus furiosus DNA polymerase mutants useful in error-prone PCR. Nucleic Acids Res, 2004; 32:e176.
40.
MiyazakiN, KiyoseN, AkazawaY, TakashimaM, HagiharaY, InoueN, MatsudaT, OgawaR, InoueS, and ItoY: Isolation and characterization of antigen-specific alpaca (Lama pacos) VHH antibodies by biopanning followed by high-Throughput sequencing. J Biochem, 2015; 158:205–215.
41.
SambrookJ, and RussellDW: Purification of Nucleic Acids by Extraction with Phenol:Chloroform. Cold Spring Harb Protoc, 2006; 2006: pii:pdb.prot4455
42.
QuanS, HinikerA, ColletJF, and BardwellJCA: Isolation of bacteria envelope proteins. Methods Mol Biol, 2013; 966:359–366.
43.
TrivediM, LaurenceJ, and SiahaanT: The Role of Thiols and Disulfides on Protein Stability. Curr Protein Pept Sci, 2009; 10:614–625.
MaloN, HanleyJA, CerquozziS, PelletierJ, and NadonR: Statistical practice in high-throughput screening data analysis. Nat Biotechnol, 2006; 24:167–175.
46.
MagdeldinS, and MoserA: Affinity Chromatography: Principles and Applications. Affinity Chromatography, 2012. [Epub ahead of print]; DOI:10.5772/39087.
47.
HaleG, DrummA, HarrisonP, and PhillipsJ: Repeated cleaning of protein A affinity column with sodium hydroxide. J Immunol Methods, 1994; 17:15–21.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
